Literature DB >> 12648033

Financial and health costs of uncontrolled blood pressure in the United Kingdom.

Adam Lloyd1, Claudia Schmieder, Nick Marchant.   

Abstract

BACKGROUND: Uncontrolled hypertension is associated with an elevated risk of all cardiovascular disease, especially stroke. However, many patients with hypertension do not achieve agreed targets for blood pressure.
OBJECTIVE: To estimate the cost and morbidity consequences of uncontrolled hypertension in the UK.
DESIGN: Descriptive epidemiological study.
METHODS: The study used a burden-of-disease model combining data on the prevalence of hypertension, the incidence of major cardiovascular (CV) events and the costs of treating these events. The prevalence of uncontrolled hypertension was taken from the 1998 Health Survey for England. The incidences of three CV events, acute myocardial infarction, congestive heart failure and stroke, at different levels of achieved blood pressure, were estimated using results from the Hypertension Optimal Treatment study. Costs were taken from published sources. We estimated the number of major CV events and acute hospital costs that would be avoided if all people with hypertension had blood pressure treated to target levels.
RESULTS: The model estimated that in the UK 5.7 million adults (12% of the population aged >16 years) have actual blood pressure above 160/95 mm Hg, and a further 10.3 million (21%) have blood pressure in the range 140/90-160/95 mm Hg. An estimated 58000 major CV events per year occur in these patients that would be avoided if their blood pressure was at target levels. If all patients had blood pressure treated to target, the cost to the NHS of managing major CV events would fall by pound 97.2 million per year at 2000/01 prices (95% CI: pound 56- pound 144 million).
CONCLUSION: Failure to achieve blood pressure targets contributes substantially to avoidable NHS costs and to the number of CV events in the UK.

Entities:  

Mesh:

Year:  2003        PMID: 12648033     DOI: 10.2165/00019053-200321001-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women.

Authors:  K Nanchahal; W D Ashton; D A Wood
Journal:  J Hypertens       Date:  2000-07       Impact factor: 4.844

3.  Cardiovascular disease costs associated with uncontrolled hypertension.

Authors:  John M Flack; Roman Casciano; Julian Casciano; James Doyle; Steven Arikian; Simon Tang; Raul Arocho
Journal:  Manag Care Interface       Date:  2002-11

Review 4.  The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension.

Authors:  L Hansson
Journal:  J Hypertens       Date:  1996-05       Impact factor: 4.844

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy.

Authors:  E Ambrosioni; G Leonetti; A C Pessina; A Rappelli; B Trimarco; A Zanchetti
Journal:  J Hypertens       Date:  2000-11       Impact factor: 4.844

Review 8.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

9.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

Review 10.  Treatment of hypertension in the elderly.

Authors:  A F Lever; L E Ramsay
Journal:  J Hypertens       Date:  1995-06       Impact factor: 4.844

View more
  5 in total

1.  Purinergic receptors in the carotid body as a new drug target for controlling hypertension.

Authors:  Wioletta Pijacka; Davi J A Moraes; Laura E K Ratcliffe; Angus K Nightingale; Emma C Hart; Melina P da Silva; Benedito H Machado; Fiona D McBryde; Ana P Abdala; Anthony P Ford; Julian F R Paton
Journal:  Nat Med       Date:  2016-09-05       Impact factor: 53.440

2.  Blood pressure status during consultation: a primary care study.

Authors:  Yousef Abdullah Al Turki
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-10-17

3.  The economic burden of stroke in the United Kingdom.

Authors:  Penny Youman; Koo Wilson; Farzaneh Harraf; Lalit Kalra
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Hypertension-associated expenditures for medication among US adults.

Authors:  Guijing Wang; Lili Yan; Carma Ayala; Mary G George; Jing Fang
Journal:  Am J Hypertens       Date:  2013-05-31       Impact factor: 2.689

5.  Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.

Authors:  Neill Booth; Antti Jula; Pasi Aronen; Minna Kaila; Timo Klaukka; Katriina Kukkonen-Harjula; Antti Reunanen; Pekka Rissanen; Harri Sintonen; Marjukka Mäkelä
Journal:  BMC Health Serv Res       Date:  2007-10-24       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.